GiannettiPPolitisMSuPet al. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain2015; 138(Pt 1): 110–119.
2.
RissanenETuiskuJRokkaJet al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand ¹¹C-PK11195. J Nucl Med2014; 55(6): 939–944.
3.
HerranzEGianniCLouapreCet al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol2016; 80(5): 776–790.
4.
DattaGColasantiARabinerEAet al. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain2017; 140(11): 2927–2938.
5.
StankoffBPoirionEToniettoMet al. Exploring the heterogeneity of MS lesions using positron emission tomography: A reappraisal of their contribution to disability. Brain Pathol2018; 28(5): 723–734.
6.
DattaGColasantiAKalkNet al. 11C-PBR28 and 18F-PBR111 detect white matter inflammatory heterogeneity in multiple sclerosis. J Nucl Med2017; 58(9): 1477–1482.
7.
BeainoWJanssenBKooijGet al. Purinergic receptors P2Y12R and P2X7R: Potential targets for PET imaging of microglia phenotypes in multiple sclerosis. J Neuroinflammation2017; 14(1): 259.
8.
BodiniBVeroneseMGarcia-LorenzoDet al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol2016; 79(5): 726–738.
9.
FreemanLGarcia-LorenzoDBottinLet al. The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study. Ann Neurol2015; 78(4): 554–567.
10.
ChenMKMeccaAPNaganawaMet al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol2018; 75(10): 1215–1224.
